ADCs targeting BCMA, CD38, CD46, CD56, CD74, CD138 are not discussed here since this special issue contains another article devoted to ADCs in multiple myeloma [184], and these targets are mainly explored in this disease setting. This evidence concerns the gene CD38 and plasma cell myeloma.